Bruker Provides Preliminary Q4 2025 Revenue and Positive FY2026 EPS & Margin Outlook

summarizeSummary

Bruker Corporation announced preliminary Q4 2025 revenue expectations and a positive outlook for full-year 2026, projecting double-digit non-GAAP EPS growth and significant operating margin expansion.

check_boxKey Events

• Preliminary Q4 2025 Revenue

  Bruker expects Q4 2025 revenue to be between $965 million and $970 million.

• Strong Book-to-Bill Ratio

  The Bruker Scientific Instruments segments reported a book-to-bill ratio above 1.0 for Q4 2025, indicating robust order intake.

• Positive FY2026 Outlook

  The company anticipates full-year 2026 organic revenue growth of flat to low-single digits, non-GAAP organic operating margins to expand by 250 to 300 basis points, and non-GAAP earnings per share to grow in the double-digits.

auto_awesomeAnalysis

Bruker's preliminary financial update, delivered at the J.P. Morgan Healthcare Conference, provides investors with key insights into its near-term performance and future trajectory. The projected double-digit non-GAAP earnings per share growth and substantial operating margin expansion for 2026 indicate a strong focus on profitability and operational efficiency. While organic revenue growth is expected to be modest, the positive book-to-bill ratio for its Scientific Instruments segments suggests healthy demand. Investors will likely view the margin and EPS guidance favorably, despite the preliminary nature of these estimates.